A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor-Reference-Cited by-同舟云学术

A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor

Published:2021-03 Issue:3 Volume:11 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Ko Young Jong¹²,Sohn Hong Moon¹²,Jang Yuria¹²,Park Mineon¹²,Kim Bora¹²,Kim Beomchang¹²,Park Jae‐Il³,Hyun Hoon⁴,Jeong Byeongseok⁵,Hong Chansik⁵,Lim Wonbong¹²⁶^ORCID

Affiliation:

1. Laboratory of Orthopaedic Research Chosun University Hospital Dong‐Gu Gwangju Republic of Korea

2. Department of Orthopaedic Surgery Chosun University Hospital Dong‐Gu Gwangju Republic of Korea

3. Korea Basic Science Institute Gwangju Center at Chonnam National University Gwangju Republic of Korea

4. Department of Biomedical Sciences Chonnam National University Medical School Gwangju Republic of Korea

5. Department of Physiology School of Medicine Chosun University Gwangju Republic of Korea

6. Department of Premedical Science College of Medicine Chosun University Dong‐Gu Gwangju Republic of Korea

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.368

Reference44 articles.

1. Bone Resorption by Osteoclasts

2. Evidence for osteocyte regulation of bone homeostasis through RANKL expression

3. Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review

4. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor

5. Osteoclasts: New Insights

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of bone homeostasis: signaling pathways and therapeutic targets;MedComm;2024-07-24

2. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor;Phytomedicine;2024-07

3. Metabolic bone disorders and the promise of marine osteoactive compounds;Cellular and Molecular Life Sciences;2023-12-20

4. An LGR4 agonist activates the GSK‑3β pathway to inhibit RANK‑RANKL signaling during osteoclastogenesis in bone marrow‑derived macrophages;International Journal of Molecular Medicine;2023-12-05

5. Molecular and Cellular Mechanisms of Osteoporosis;International Journal of Molecular Sciences;2023-10-30